Can European VCs and Universities Make Money from New Biotech Spin-Offs?
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 66 (Table of Contents)
Published: 1 Dec-2005
DOI: 10.3833/pdr.v2005.i66.586 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Dr Jonathan Savidge, of UCL Biomedica, makes the point that the ability of early-stage biotechs, in particular spin-offs from universities, to obtain VC financing, depends on these investors being able to secure successful exits - either via IPOs or M&As...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS